Global Human Oocyte Cryopreservation 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI01251675

Publication Date:

January 20, 2025

Pages:

139

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Human Oocyte Cryopreservation market size is predicted to grow from US$ 89 million in 2025 to US$ 212 million in 2031; it is expected to grow at a CAGR of 15.6% from 2025 to 2031.
Human oocyte cryopreservation (egg freezing) is a procedure to preserve female eggs (oocytes). The eggs are extracted, frozen and stored. The purpose of the procedure is to give women the option of thawing, fertilizing and transplanting the eggs into the uterus as embryos to promote future pregnancy.
Oocyte cryopreservation refers to the technology of cooling human oocytes and storing them in liquid nitrogen (generally stored in liquid nitrogen at -196掳C), resuscitating (thawing) them when needed, and ensuring that the oocytes are alive and functioning normally. It is a derivative technology of assisted reproductive technology, mainly used to treat infertility and preserve female fertility.
The driving factors of the oocyte cryopreservation market mainly include the following aspects:
Technological progress
The continuous improvement and maturity of oocyte cryopreservation technology has improved the recovery rate and survival rate of frozen oocytes, thereby increasing the clinical application prospects of this technology and driving the development of the market.
Changes in fertility concepts
The changes in modern women's fertility concepts and the intensification of the trend of late marriage and late childbearing have led more and more women to choose oocyte cryopreservation technology to maintain fertility and provide guarantees for future fertility plans.
Growth in medical demand
With the improvement of medical standards and people's attention to reproductive health, more and more medical institutions and patients have begun to pay attention to oocyte cryopreservation technology, which has promoted the rapid development of the market.
Policy support
The support policies of some countries and regions for assisted reproductive technology, as well as the improvement of relevant laws and regulations, have provided a good policy environment for the development of oocyte cryopreservation technology.
Unlike sperm, oocytes are larger and contain a lot of water, which makes it easier to form ice crystals that may damage the eggs during the freezing process. In addition, egg extraction is not easy and the number is scarce, so the selection of protective agents during the freezing process is also more demanding. These factors have made egg freezing one of the difficulties in freezing technology.
However, with the continuous advancement of technology, the success rate of oocyte cryopreservation has been significantly improved. International clinical trials have proven that frozen eggs can be stored for at least ten years, and they still have the ability to conceive after thawing, can form healthy embryos, and can normally conceive babies. This has led more and more women to choose to preserve their future reproductive ability through oocyte cryopreservation technology, that is, to buy a "fertility insurance".
In general, oocyte cryopreservation technology provides an effective option for women who want to preserve their fertility, and also provides new possibilities for the development of assisted reproductive technology.
The 鈥淗uman Oocyte Cryopreservation Industry Forecast鈥� looks at past sales and reviews total world Human Oocyte Cryopreservation sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Oocyte Cryopreservation sales for 2025 through 2031. With Human Oocyte Cryopreservation sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Oocyte Cryopreservation industry.
This Insight Report provides a comprehensive analysis of the global Human Oocyte Cryopreservation landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Human Oocyte Cryopreservation portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Human Oocyte Cryopreservation market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Oocyte Cryopreservation and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Oocyte Cryopreservation.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Oocyte Cryopreservation market by product type, application, key players and key regions and countries.
Segmentation by Type:
Slow-cooling Method
Flash-freezing Process (Vitrification)
Segmentation by Application:
25-30 Year Old Female
30-35 Year Old Female
35-40 Year Old Female
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Anova Fertility
CCRM IVF
Chill
CREATE Fertility
Extend Fertility
HRC Fertility
IVF Australia
Kindbody
London Women鈥檚 Clinic
Manchester Fertility
Mayo Clinic
Melbourne IVF
Monash IVF
Pacific Fertility Center-Los Angeles (PFCLA)
PIVET
Prelude Fertility

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Human Oocyte Cryopreservation 麻豆原创 Size (2020-2031)
2.1.2 Human Oocyte Cryopreservation 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Human Oocyte Cryopreservation by Country/Region (2020, 2024 & 2031)
2.2 Human Oocyte Cryopreservation Segment by Type
2.2.1 Slow-cooling Method
2.2.2 Flash-freezing Process (Vitrification)
2.3 Human Oocyte Cryopreservation 麻豆原创 Size by Type
2.3.1 Human Oocyte Cryopreservation 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Human Oocyte Cryopreservation 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Human Oocyte Cryopreservation Segment by Application
2.4.1 25-30 Year Old Female
2.4.2 30-35 Year Old Female
2.4.3 35-40 Year Old Female
2.4.4 Others
2.5 Human Oocyte Cryopreservation 麻豆原创 Size by Application
2.5.1 Human Oocyte Cryopreservation 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Human Oocyte Cryopreservation 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Human Oocyte Cryopreservation 麻豆原创 Size by Player
3.1 Human Oocyte Cryopreservation 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Human Oocyte Cryopreservation Revenue by Player (2020-2025)
3.1.2 Global Human Oocyte Cryopreservation Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Human Oocyte Cryopreservation Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Human Oocyte Cryopreservation by Region
4.1 Human Oocyte Cryopreservation 麻豆原创 Size by Region (2020-2025)
4.2 Global Human Oocyte Cryopreservation Annual Revenue by Country/Region (2020-2025)
4.3 Americas Human Oocyte Cryopreservation 麻豆原创 Size Growth (2020-2025)
4.4 APAC Human Oocyte Cryopreservation 麻豆原创 Size Growth (2020-2025)
4.5 Europe Human Oocyte Cryopreservation 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Human Oocyte Cryopreservation 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Human Oocyte Cryopreservation 麻豆原创 Size by Country (2020-2025)
5.2 Americas Human Oocyte Cryopreservation 麻豆原创 Size by Type (2020-2025)
5.3 Americas Human Oocyte Cryopreservation 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Oocyte Cryopreservation 麻豆原创 Size by Region (2020-2025)
6.2 APAC Human Oocyte Cryopreservation 麻豆原创 Size by Type (2020-2025)
6.3 APAC Human Oocyte Cryopreservation 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Human Oocyte Cryopreservation 麻豆原创 Size by Country (2020-2025)
7.2 Europe Human Oocyte Cryopreservation 麻豆原创 Size by Type (2020-2025)
7.3 Europe Human Oocyte Cryopreservation 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Human Oocyte Cryopreservation by Region (2020-2025)
8.2 Middle East & Africa Human Oocyte Cryopreservation 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Human Oocyte Cryopreservation 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Human Oocyte Cryopreservation 麻豆原创 Forecast
10.1 Global Human Oocyte Cryopreservation Forecast by Region (2026-2031)
10.1.1 Global Human Oocyte Cryopreservation Forecast by Region (2026-2031)
10.1.2 Americas Human Oocyte Cryopreservation Forecast
10.1.3 APAC Human Oocyte Cryopreservation Forecast
10.1.4 Europe Human Oocyte Cryopreservation Forecast
10.1.5 Middle East & Africa Human Oocyte Cryopreservation Forecast
10.2 Americas Human Oocyte Cryopreservation Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Human Oocyte Cryopreservation Forecast
10.2.2 Canada 麻豆原创 Human Oocyte Cryopreservation Forecast
10.2.3 Mexico 麻豆原创 Human Oocyte Cryopreservation Forecast
10.2.4 Brazil 麻豆原创 Human Oocyte Cryopreservation Forecast
10.3 APAC Human Oocyte Cryopreservation Forecast by Region (2026-2031)
10.3.1 China Human Oocyte Cryopreservation 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Human Oocyte Cryopreservation Forecast
10.3.3 Korea 麻豆原创 Human Oocyte Cryopreservation Forecast
10.3.4 Southeast Asia 麻豆原创 Human Oocyte Cryopreservation Forecast
10.3.5 India 麻豆原创 Human Oocyte Cryopreservation Forecast
10.3.6 Australia 麻豆原创 Human Oocyte Cryopreservation Forecast
10.4 Europe Human Oocyte Cryopreservation Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Human Oocyte Cryopreservation Forecast
10.4.2 France 麻豆原创 Human Oocyte Cryopreservation Forecast
10.4.3 UK 麻豆原创 Human Oocyte Cryopreservation Forecast
10.4.4 Italy 麻豆原创 Human Oocyte Cryopreservation Forecast
10.4.5 Russia 麻豆原创 Human Oocyte Cryopreservation Forecast
10.5 Middle East & Africa Human Oocyte Cryopreservation Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Human Oocyte Cryopreservation Forecast
10.5.2 South Africa 麻豆原创 Human Oocyte Cryopreservation Forecast
10.5.3 Israel 麻豆原创 Human Oocyte Cryopreservation Forecast
10.5.4 Turkey 麻豆原创 Human Oocyte Cryopreservation Forecast
10.6 Global Human Oocyte Cryopreservation Forecast by Type (2026-2031)
10.7 Global Human Oocyte Cryopreservation Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Human Oocyte Cryopreservation Forecast
11 Key Players Analysis
11.1 Anova Fertility
11.1.1 Anova Fertility Company Information
11.1.2 Anova Fertility Human Oocyte Cryopreservation Product Offered
11.1.3 Anova Fertility Human Oocyte Cryopreservation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Anova Fertility Main Business Overview
11.1.5 Anova Fertility Latest Developments
11.2 CCRM IVF
11.2.1 CCRM IVF Company Information
11.2.2 CCRM IVF Human Oocyte Cryopreservation Product Offered
11.2.3 CCRM IVF Human Oocyte Cryopreservation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 CCRM IVF Main Business Overview
11.2.5 CCRM IVF Latest Developments
11.3 Chill
11.3.1 Chill Company Information
11.3.2 Chill Human Oocyte Cryopreservation Product Offered
11.3.3 Chill Human Oocyte Cryopreservation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Chill Main Business Overview
11.3.5 Chill Latest Developments
11.4 CREATE Fertility
11.4.1 CREATE Fertility Company Information
11.4.2 CREATE Fertility Human Oocyte Cryopreservation Product Offered
11.4.3 CREATE Fertility Human Oocyte Cryopreservation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 CREATE Fertility Main Business Overview
11.4.5 CREATE Fertility Latest Developments
11.5 Extend Fertility
11.5.1 Extend Fertility Company Information
11.5.2 Extend Fertility Human Oocyte Cryopreservation Product Offered
11.5.3 Extend Fertility Human Oocyte Cryopreservation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Extend Fertility Main Business Overview
11.5.5 Extend Fertility Latest Developments
11.6 HRC Fertility
11.6.1 HRC Fertility Company Information
11.6.2 HRC Fertility Human Oocyte Cryopreservation Product Offered
11.6.3 HRC Fertility Human Oocyte Cryopreservation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 HRC Fertility Main Business Overview
11.6.5 HRC Fertility Latest Developments
11.7 IVF Australia
11.7.1 IVF Australia Company Information
11.7.2 IVF Australia Human Oocyte Cryopreservation Product Offered
11.7.3 IVF Australia Human Oocyte Cryopreservation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 IVF Australia Main Business Overview
11.7.5 IVF Australia Latest Developments
11.8 Kindbody
11.8.1 Kindbody Company Information
11.8.2 Kindbody Human Oocyte Cryopreservation Product Offered
11.8.3 Kindbody Human Oocyte Cryopreservation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Kindbody Main Business Overview
11.8.5 Kindbody Latest Developments
11.9 London Women鈥檚 Clinic
11.9.1 London Women鈥檚 Clinic Company Information
11.9.2 London Women鈥檚 Clinic Human Oocyte Cryopreservation Product Offered
11.9.3 London Women鈥檚 Clinic Human Oocyte Cryopreservation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 London Women鈥檚 Clinic Main Business Overview
11.9.5 London Women鈥檚 Clinic Latest Developments
11.10 Manchester Fertility
11.10.1 Manchester Fertility Company Information
11.10.2 Manchester Fertility Human Oocyte Cryopreservation Product Offered
11.10.3 Manchester Fertility Human Oocyte Cryopreservation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Manchester Fertility Main Business Overview
11.10.5 Manchester Fertility Latest Developments
11.11 Mayo Clinic
11.11.1 Mayo Clinic Company Information
11.11.2 Mayo Clinic Human Oocyte Cryopreservation Product Offered
11.11.3 Mayo Clinic Human Oocyte Cryopreservation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Mayo Clinic Main Business Overview
11.11.5 Mayo Clinic Latest Developments
11.12 Melbourne IVF
11.12.1 Melbourne IVF Company Information
11.12.2 Melbourne IVF Human Oocyte Cryopreservation Product Offered
11.12.3 Melbourne IVF Human Oocyte Cryopreservation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Melbourne IVF Main Business Overview
11.12.5 Melbourne IVF Latest Developments
11.13 Monash IVF
11.13.1 Monash IVF Company Information
11.13.2 Monash IVF Human Oocyte Cryopreservation Product Offered
11.13.3 Monash IVF Human Oocyte Cryopreservation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Monash IVF Main Business Overview
11.13.5 Monash IVF Latest Developments
11.14 Pacific Fertility Center-Los Angeles (PFCLA)
11.14.1 Pacific Fertility Center-Los Angeles (PFCLA) Company Information
11.14.2 Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Product Offered
11.14.3 Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Pacific Fertility Center-Los Angeles (PFCLA) Main Business Overview
11.14.5 Pacific Fertility Center-Los Angeles (PFCLA) Latest Developments
11.15 PIVET
11.15.1 PIVET Company Information
11.15.2 PIVET Human Oocyte Cryopreservation Product Offered
11.15.3 PIVET Human Oocyte Cryopreservation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 PIVET Main Business Overview
11.15.5 PIVET Latest Developments
11.16 Prelude Fertility
11.16.1 Prelude Fertility Company Information
11.16.2 Prelude Fertility Human Oocyte Cryopreservation Product Offered
11.16.3 Prelude Fertility Human Oocyte Cryopreservation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Prelude Fertility Main Business Overview
11.16.5 Prelude Fertility Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.